Ono Pharmaceutical Rolls Out Agentic AI Across Drug Discovery

Ono Pharmaceutical will deploy Phylo's agentic AI platform Biomni Lab across its drug discovery organization under a collaboration announced July 28, 2026, aiming to automate the full computational workflow of discovery scientists. The Osaka-based drugmaker is integrating the South San Francisco applied-AI lab's platform to synthesize experimental history and streamline early-stage research.

Ono Pharmaceutical is putting AI agents in front of the scientists who run its earliest-stage research. Under a collaboration announced on July 28, 2026, the Osaka drugmaker will deploy Biomni Lab, the agentic research platform built by South San Francisco applied-AI lab Phylo, across its drug discovery organization. What the platform is meant to absorb, according to the announcement, is the full span of a discovery scientist's computational day: synthesizing a program's experimental history…